Arca
Skip to content
Tools
Tools

CD47: Leukocyte surface antigen CD47

Adhesive protein that mediates cell-to-cell interactions.

  • Drugs that act on it: 2
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on CD47, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Protein or peptide 1

Approved0

    Phase 31

    • Magrolimab

    Phase 21

    • Evorpacept

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      MagrolimabPhase 3Ono PharmaceuticalAntibodyInhibitorLeukocyte surface antigen CD47 inhibitor2
      EvorpaceptPhase 2Alx Oncology HoldingsProtein or peptideInhibitorLeukocyte surface antigen CD47 inhibitor7

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
      ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerEvorpaceptPhase 2RecruitingALX Oncology Inc.Jun 6, 2025
      The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal CancerMagrolimabPhase 1Active, not recruitingOno Pharmaceutical Co., Ltd.Aug 6, 2024
      An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic CancerMagrolimabPhase 1Active, not recruitingOno Pharmaceutical Co., Ltd.Aug 1, 2024
      PRE-ISPY Phase I/II Oncology Platform ProgramEvorpaceptPhase 1 / Phase 2RecruitingQuantumLeap Healthcare CollaborativeMay 22, 2023
      Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)EvorpaceptPhase 2Active, not recruitingUniversity of California, San DiegoMar 28, 2023
      Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian CancerEvorpaceptPhase 2Active, not recruitingAlexander B Olawaiye, MDJul 20, 2022
      Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)EvorpaceptPhase 2Active, not recruitingALX Oncology Inc.Dec 19, 2020
      Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)EvorpaceptPhase 2Active, not recruitingALX Oncology Inc.Dec 19, 2020
      Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolEvorpaceptPhase 1 / Phase 2RecruitingSanofiNov 24, 2020

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Smoking initiation0.34
      • Abnormality of refraction0.29
      • Hypothyroidism0.28
      • Iron metabolism disease0.28
      • Acute myeloid leukemia by FAB classification0.27
      • Color vision disorder0.24

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3714583, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q08722, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.